Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 1997

View Archived Issues

Company Profile: Elan

Novo Nordisk develops A1 agonist with neuroprotectant activity

Efficacy of TxA2 antagonist in IBD established

New muscarinic compound from Wyeth-Ayerst

TheraTech: Q3 1997 highlights

ImClone Systems: Q3 1997 highlights

Pfizer improves on NMDA antagonists

Promising results reported from pilot trial of Repel

Enzon: Q1 1998 highlights

New antihyperalgesic agents from Adolor

NPS and SmithKline Beecham sign additional extension of osteoporosis agreement

Novel valproic acid prodrug reported at scientific meeting

Preclinical profile of Novartis' dermatology candidate

AMPA antagonist investigated for treatment of drug withdrawal

Safe and effective new D2 partial agonist in development at Wyeth-Ayerst

Alteon prepares new AGE inhibitors

CRF antagonists from DuPont Merck for anxiety, depression and related disorders

Lilly discovers highly potent and selective NPY Y1 receptor antagonists

Adefovir dipivoxil now available in expanded access program

Seragen submits BLA for CTCL biological product

Novel liver-targeted conjugate for hepatitis B virus infection

Preclinical toxicity profile of ISIS-2503

BioTime reports preliminary phase III data from Hextend trial

FDA approves shorter treatment claim for Mentax

Boehringer Mannheim returns to PDL rights to two antiviral compounds

StressGen prepares to evaluate Oncocine in clinical trials

FDA advisory committee recommends approval of TOBI

Propecia recommended for approval for hair loss in men

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 7, 2025.
House passes H.R. 1, restoring R&D tax cuts
BioWorld MedTech
The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
With surface mimicry, molecular glues shed hairpin need
BioWorld Science
Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
Exercise-mimicking compound offers alternative to GLP-1 therapies
BioWorld
An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...